Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Interest Expenses (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Interest Expenses for 7 consecutive years, with $13000.0 as the latest value for Q1 2026.

  • For Q1 2026, Interest Expenses changed 0.0% year-over-year to $13000.0; the TTM value through Mar 2026 reached $51000.0, down 5.56%, while the annual FY2025 figure was $51000.0, 3.77% down from the prior year.
  • Interest Expenses hit $13000.0 in Q1 2026 for Barinthus Biotherapeutics, roughly flat from $13000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $74000.0 in Q1 2022 and bottomed at $7000.0 in Q3 2023.
  • Average Interest Expenses over 5 years is $16846.2, with a median of $13000.0 recorded in 2025.
  • Year-over-year, Interest Expenses crashed 97.21% in 2022 and then surged 142.86% in 2024.
  • Barinthus Biotherapeutics' Interest Expenses stood at $74000.0 in 2022, then tumbled by 90.54% to $7000.0 in 2023, then surged by 71.43% to $12000.0 in 2024, then increased by 8.33% to $13000.0 in 2025, then changed by 0.0% to $13000.0 in 2026.
  • According to Business Quant data, Interest Expenses over the past three periods came in at $13000.0, $13000.0, and $13000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.